Last reviewed · How we verify
NCT07239973
A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects
Phase 1 trial testing BGM0504 tablets in Healthy in 75 participants. Currently enrolling.
31 March 2026
Quick facts
| Lead sponsor | BrightGene Bio-Medical Technology Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 75 |
| Start date | 21 October 2025 |
| Primary completion | 31 March 2026 |
| Estimated completion | 31 March 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- BGM0504 tablets — full drug profile →
- Placebo tablets — full drug profile →
Conditions studied
- Healthy — all drugs for Healthy →
- Non-diabetic Overweight or Obese — all drugs for Non-diabetic Overweight or Obese →
Sponsor
BrightGene Bio-Medical Technology Co., Ltd. — full company profile →
Who can join
Adults 18 to 55, any sex, with Healthy or Non-diabetic Overweight or Obese. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Randomized, Double-Blind, Placebo-Controlled, Single/Multiple-dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BGM0504 Tablets Orally Administered in Healthy and Non-diabetic Overweight or Obese Chinese Subjects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07239973
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other BrightGene Bio-Medical Technology Co., Ltd. trials
Trials by the same sponsor.
- NCT07382908 — Bioequivalence Study of BGM0504 Injection · Phase 1 · recruiting
- NCT07294235 — A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants · Phase 1 · recruiting
- NCT07224399 — Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multi · Phase 1 · recruiting
- NCT07166081 — Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight o · Phase 1 · recruiting
- NCT07064486 — A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07239973 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BrightGene Bio-Medical Technology Co., Ltd.
- Last refreshed: 20 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07239973.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing